Nuvama sees 37% upside in this healthcare stock. Should you buy?
Analysis of this story by livemint_markets · 11 Mar 2026, 3:17 PM IST (about 2 months ago)
AI Analysis
Despite broader market concerns due to geopolitical tensions (Iran War), specific sector-driven opportunities like healthcare are emerging. Analyst recommendations can provide pockets of strength amidst overall market weakness.
Trading Insight
Look for healthcare stocks with strong fundamentals and positive analyst coverage, potentially outperforming the Nifty/Sensex in a volatile environment.
Quick check: MAXHEALTH neutral (+0.4% 1d), NIFTY neutral.
Key Evidence
- •Nuvama initiated coverage on Park Medi World with a 'Buy' rating.
- •Nuvama set a target price of ₹280, projecting a 37% upside.
- •Park Medi World is expected to benefit from India's hospital bed shortage and growth in Tier II markets.
- •The company plans to significantly expand its bed capacity by FY28.
- •Risk flag: Broader market volatility due to geopolitical events (Iran War)
Affected Stocks
Positive
Nuvama initiated coverage with a 'Buy' rating and a 37% upside target, citing expansion plans and market opportunity.
MAXHEALTHMax Healthcare Institute Ltd.
Positive
Online context shows Nuvama also gave a 'Buy' call for Max Healthcare, indicating a positive sentiment towards the healthcare sector.
Sources and updates
Original source: livemint_markets
Published: 11 Mar 2026, 3:17 PM IST
Last updated on Anadi News: 11 Mar 2026, 3:19 PM IST
AI-powered analysis by
Anadi Algo News